Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Codice etico e Modello 231

Philogen to attend the 13th World ADC San Diego 2022, San Diego, USA (6-9 September 2022)

Jun 27, 2022 | 2022, Events, Scientific

Philogen will attend the 13th World ADC in San Diego (USA) in September 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture in person entitled “Pan-Tumoral Small Molecule-Drug Conjugates Targeting Fibroblasts Activation...

Philogen receives authorisation to initiate new study in France to evaluate Nidlegy™ in several non-melanoma skin cancers

Feb 17, 2022 | Press Releases, Scientific

More details

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

Jan 7, 2022 | Press Releases, Scientific

More info here

Philogen announces new collaboration with Janssen to discover small molecule therapeutics

Nov 24, 2021 | 2021, Press Releases, Scientific

More datails

Philogen provides Corporate Update

Nov 12, 2021 | 2021, Press Releases, Scientific

Philogen to hold a Webinar at 11 am EST / 4 pm GMT / 5 pm CET on Friday 12th November 2021, Click here to view Press Release 12-11-2021

Philogen to attend the Cytokine-Based Cancer Immunotherapies Summit on November 30-December 2 , 2021

Nov 4, 2021 | 2021, Past Events, Scientific

Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...
« Older Entries

Recent Posts

  • 27 giugno 2022 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen to the 12th European Post-Chicago Melanoma/Skin Cancer Meeting, 30-1 July
  • Philogen to attend the 3rd Annual Cytokine-Based Drug Development Summit, Boston (July 26-29, 2022)
  • Philogen to attend the 13th World ADC San Diego 2022, San Diego, USA (6-9 September 2022)
  • Philogen to attend EANO Congress in Vienna, Austria (15-18 September 2022)

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it